Literature DB >> 30508184

Development and validation of a nomogram incorporating axillary lymph node ratio to predict survival in node-positive breast cancer patients after neoadjuvant chemotherapy.

Jianguo Lai1,2, Zihao Pan1,3, Peixian Chen4, Guolin Ye4, Kai Chen1,2, Fengxi Su1,2.   

Abstract

OBJECTIVE: Over the past decade, several studies have highlighted that axillary lymph node ratio (ratio of involved over excised axillary lymph nodes) was a superior predictor for survival outcomes compared with ypN staging. Thus, this study aimed to integrate the prognostic value of axillary lymph node ratio to improve individualized prediction of survival in node-positive breast cancer patients after neoadjuvant chemotherapy.
METHODS: A clinical data of 339 node-positive breast cancer patients after neoadjuvant chemotherapy from two independent centers were retrospectively reviewed. A nomogram incorporating axillary lymph node ratio was constructed to predict disease-free survival based on Cox proportional hazards model. The discrimination, calibration ability, and clinical usefulness of the axillary lymph node ratio-based model were evaluated using C-index, calibration curve, risk group stratification and decision curve analysis and were compared with the TNM staging system.
RESULTS: Independent prognostic factors for disease-free survival were age, pathological T stage, axillary lymph node ratio, histological grade, estrogen receptor status, Ki67 and lymphovascular invasion, which were entered into the nomogram. The C-index of the axillary lymph node ratio-based nomogram was higher than that of the TNM staging system (0.773 vs 0.610). The calibration plot indicated close agreement between model predictions and actual observations. Based on the risk group stratification of the nomogram, Kaplan-Meier curves demonstrated significant differences between the low-risk and high-risk groups (P < 0.0001).
CONCLUSIONS: The axillary lymph node ratio-based nomogram provided more accurate individualized risk prediction of disease-free survival in node-positive breast cancer patients after neoadjuvant chemotherapy. This practical tool may assist oncologists in selecting the high-risk patients who are in need of a specific treatment strategy.

Entities:  

Mesh:

Year:  2019        PMID: 30508184     DOI: 10.1093/jjco/hyy181

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  4 in total

1.  Supervised Machine Learning Predictive Analytics For Triple-Negative Breast Cancer Death Outcomes.

Authors:  Yucan Xu; Lingsha Ju; Jianhua Tong; Chengmao Zhou; Jianjun Yang
Journal:  Onco Targets Ther       Date:  2019-11-01       Impact factor: 4.147

2.  Molecular characterization of breast cancer: a potential novel immune-related lncRNAs signature.

Authors:  Jianguo Lai; Bo Chen; Guochun Zhang; Xuerui Li; Hsiaopei Mok; Ning Liao
Journal:  J Transl Med       Date:  2020-11-07       Impact factor: 5.531

3.  The Efficacy of Pegylated Liposomal Doxorubicin-Based Neoadjuvant Chemotherapy in Breast Cancer: A Retrospective Case-Control Study in Taiwan.

Authors:  Chih-Chiang Hung; Youngsen Yang; I-Chen Tsai; Chiann-Yi Hsu; Chia-Hua Liu; Jie-Ru Yang
Journal:  Biochem Res Int       Date:  2020-04-28

4.  A Model for the Prediction of Survival in Patients With Upper Tract Urothelial Carcinoma After Surgery.

Authors:  Guang-Lin Zhang; Wei Zhou
Journal:  Dose Response       Date:  2019-10-14       Impact factor: 2.658

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.